07.25.12
Alexion
2Q Revenues: $274.7 million (+48%)
2Q Earnings: $36.3 million (+5%)
YTD Revenues: $519.5 million (+48%)
YTD Earnings: $81.7 million (+33%)
Comments: Revenues were driven by Soliris, which added the indication of atypical hemolytic uremic syndrome late last year. R&D expenses rose 70% to $60 million as the company advanced several drugs in its pipeline.
2Q Revenues: $274.7 million (+48%)
2Q Earnings: $36.3 million (+5%)
YTD Revenues: $519.5 million (+48%)
YTD Earnings: $81.7 million (+33%)
Comments: Revenues were driven by Soliris, which added the indication of atypical hemolytic uremic syndrome late last year. R&D expenses rose 70% to $60 million as the company advanced several drugs in its pipeline.